Passage Bio Inc PASG

$4.55 +0.86 (23.31%)

Valuation

Market cap
11,874,000
Revenue TTM
$0
Net income TTM
$-45,520,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
75,217
Avg volume
20,350
Day's range
$3.60 – $4.55
Shares out
3,218,000
Stochastic %K
6%
Beta
1.40
Analysts
Sell
Price target
$13.33

Price

Company profile

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatme...

Show more

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
267 866 0311
Website
https://www.passagebio.com
Address
One Commerce Square, 2005 Market Street 39th Floor, Philadelphia, United States

Latest news

Stocktwits

MouseR Aug 10, 2:29 AM
$PASG Any idea what may happen with our shares upon merger ?
2 replies
skyrockets_Inc Jun 29, 4:36 PM
$NEUP Just getting back from Vegas and doing reviewing this. Still not completely up to speed but a few things I noticed and can comment my opinion on. 1). Why this random British company that has no focus in CNS / Neuro? There are dozens upon dozens of private companies out there looking to RM in the US. Would have been a lot easier and quicker. $PASG and a few others just did RMs and it only took them 3 months. But they did not have valuable assets to deal with. So why the British company? Is there some connection w/ the CEO and the MK-1167 asset? Or something else going on ? 2). This is already trading on GBX exchange under ticker $SCLP. This is unique because we are able to see the market cap is 250M USD. Likely in a RM, they will get additional funding throuhg PIPE and the valuation may be higher ...say 300-400M USD. We are sitting at 25M market cap right now so we need to get a % that would equate to 25M just to break even. So likely upper single digits...
0 replies
stu4 Jun 25, 8:42 PM
$PASG @jacksparo all beat up a Johnny come lately
0 replies
stu4 Jun 25, 8:32 PM
Liar pants on fire , like your claim at $PASG
2 replies
Rfv Jun 25, 7:17 PM
$PASG Kraken 👀🌋🌋🌋
0 replies
Rumpelstwitskin Jun 25, 6:00 PM
$PASG going to 7 this news is positive
0 replies
Rfv Jun 25, 5:43 PM
$PASG 🌋🌋🚀🚀🚀👀👀👀😏
0 replies
Trendrebel Jun 25, 3:30 PM
$PASG total overreaction. Reverse merger has never been popular. Though, I think 7% is way too less. Better let SEC check up, what might be behind the curtain from a CEO without a single stock. I dont think Lynx is happy about this.
0 replies